NBE Therapeutics Closes a CHF 20 Million Financing by Novo Holdings A/S
NBE Therapeutics AG, a biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) for improved cancer therapy, today announces a CHF 20 mill...
Continue Reading →
